Redefining Drug Delivery Through Integrated Design-to-Manufacture

World Pharma Today features Ensera CEO Jason Anderson on integrated design-to-manufacture, digital quality systems and faster pathways for drug delivery device

Sanofi, Earendil Partner on Autoimmune Disease Treatments

Sanofi and Earendil Labs have announced a collaboration worth $2.5 billion on autoimmune disease treatments by focusing on developing bispecific antibodies.

Revvity and Lilly Expand Lilly TuneLab Access via Signals

Revvity and Eli Lilly expand Lilly TuneLab access by adding it to the Revvity Signals platform, supporting federated AI use across drug discovery programs.

Amgen Eyeing Preclinical Blood Cancer Program to Its Skills

Amgen is going ahead and adding Dark Blue to its tapestry, embedding the preclinical blood cancer program of U.K. biotech into its organization. The California pharma has gone ahead and stitched together a deal of almost $840 million for Dark Blue Therapeutics, which is a private biotech based out of Oxford. The aim of the biotech is to come

InduPro, Lilly Partner to Discover Novel Cancer Treatments

Shortly after going ahead and securing a partnership with Sanofi, InduPro is now linking up with Eli Lilly in its endeavors to discover novel cancer treatments through a pact that could as well be worth almost $950 million. InduPro is going to work with the Big Pharma company on around three undisclosed cancer targets, as

Nimbus, Lilly Ink Licence Agreement on Treatments in Obesity

Nimbus Therapeutics has announced that it has entered into a multi-year research partnership and a $1.3 billion exclusive license agreement with Eli Lilly in order to develop oral treatments in obesity as well as other metabolic diseases. Lilly, which very recently went ahead and announced the topline results coming from its phase III trial studying Orforglipron,